RAD 140, also known as Testolone, is a selective androgen receptor modulator (SARM) being researched for possible application in the treatment of muscle wasting and osteoporosis. The FDA has not cleared it for human consumption or usage, and its long-term consequences on human health are unknown.
RAD 140, like other selective androgen receptor modulators (SARMs), operates in the body by preferentially targeting and binding to androgen receptors. Androgen receptors may be found all over the body, including muscle tissue, bone tissue, and reproductive organs. When RAD 140 interacts with these receptors, it causes a chain of chemical processes that can lead to greater muscle development, bone density, and athletic performance.
In contrast to anabolic steroids, which can induce a variety of unpleasant side effects due to their non-selective binding to androgen receptors throughout the body, SARMs such as RAD 140 are meant to be more selective in their targeting of certain androgen receptors. This selectivity is expected to lower the probability of unfavorable side effects while still offering many of the anabolic steroid advantages.
In clinical trials, RAD 140 was given to people at dosages ranging from 0.1 to 30 mg per day. Nevertheless, these studies have mostly focused on short-term results and have been done on small samples of healthy adults.
The potential therapeutic advantages of RAD 140, like other selective androgen receptor modulators (SARMs), are being investigated. While the long-term consequences on human health are unknown, some of the possible advantages reported in animal and human research include:
While RAD 140 may have some potential advantages, its long-term effects on human health are unknown, and the FDA has not cleared its usage for human ingestion or use. Like with any supplement or medication, there is the possibility of negative effects with RAD 140, which include: